• SLIDE 2: Objectives • SLIDE 3: History of Present Illness • SLIDE 4: Past Medical History • SLIDE 5: Personal and Social History; Family History • SLIDE 6: Physical Examination • SLIDE 7: Primary Impression/Diagnosis • SLIDE 8-9: Differential Diagnosis (Give at least 3) • SLIDE 10: Interpretation of results (Lab and Imaging studies given in the case) • SLIDE 11: Final Impression/Diagnosis • CASE DICUSSION o SLIDE 12-13: Brief Anatomy and Physiology o SLIDE 14-15: Definition of Disease and Pathophysiology (including etiology and risk factors) o SLIDE 16: Diagnostics (Ideal Laboratory and Imaging studies) o SLIDE 17-23: Management ▪ Pre-operative management (when applicable) ▪ Neoadjuvant treatment (when applicable) ▪ Surgical Treatment (including descriptions of surgical procedure) ▪ Post-operative Complications and Management ▪ Adjuvant Therapy and Surveillance (when applicable) • SLIDE 24-25: Case Resolution o Complete management plan for the patient.. Give me very detailed explained with images according to this case for the above question for a surgery in reference to schwarts surgery...give me fast
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Searching Images
appendix carcinoid neuroendocrine tumor histology
Finding Sources
Finding Sources
Searching Images
appendix anatomy location cecum mesoappendix
Searching Images
right hemicolectomy surgical procedure steps
Searching Images
appendix neuroendocrine tumor chromogranin synaptophysin immunohistochemistry
Searching Images
octreotide scan somatostatin receptor scintigraphy neuroendocrine tumor
Finding Sources
Finding Sources
Running Command
Running Command
Give me explanation not made ppt.. just explaination and answer for those
Searching Images
appendix anatomy vermiform cecum ileocecal valve
Searching Images
appendiceal neuroendocrine carcinoid tumor histology salt pepper nuclei
Here is the complete, detailed explanation for all slides based on the case of J.C., 25-year-old male, post-Open Appendectomy, with final histopath confirming Appendiceal Neuroendocrine Tumor (Carcinoid). All content is referenced to Schwartz's Principles of Surgery.
MODULE 6: SMALL INTESTINE AND APPENDIX — CASE 5
Complete Slide-by-Slide Explanation
SLIDE 1: TITLE SLIDE
Title: Appendiceal Neuroendocrine Tumor (Carcinoid): A Surgical Case Discussion
Case: J.C., 25-year-old male, post-Open Appendectomy for Acute Appendicitis — incidental carcinoid on final histopath
Reference: Schwartz's Principles of Surgery, 11th Edition
SLIDE 2: OBJECTIVES
By the end of this case presentation, the learner should be able to:
- Identify the clinical presentation of acute appendicitis and its mimickers
- Recognize the histopathologic features of appendiceal neuroendocrine tumors (NETs/carcinoids)
- Interpret gross and microscopic pathological findings of incidentally discovered appendiceal carcinoid
- Discuss the differential diagnosis for right lower quadrant pain
- Formulate a complete diagnostic and management plan for appendiceal NET based on tumor size and staging
- Understand the indications for appendectomy alone vs. right hemicolectomy in appendiceal NETs
- Outline adjuvant therapy, surveillance, and follow-up for appendiceal neuroendocrine tumors
SLIDE 3: HISTORY OF PRESENT ILLNESS (HPI)
Patient: J.C., 25-year-old male
Chief Complaint: Follow-up consult, 1 week post-operatively
History:
- Patient was admitted 1 week prior with complaints of:
- Fever (exact temperature not recorded at first admission)
- Right Lower Quadrant (RLQ) pain
- Clinical diagnosis of Acute Appendicitis was made
- Patient underwent Open Appendectomy
- On follow-up visit today:
- Wound is well-coaptated
- No complaints of post-operative pain
- Patient is afebrile, vitally stable
- Patient brought the final histopathology result which revealed an incidental finding
Key Surgical Note: The primary reason for surgery was acute appendicitis. The carcinoid/NET was an incidental finding on final histopath — a classic scenario in clinical surgery, occurring in approximately 0.3–0.9% of appendectomy specimens.
SLIDE 4: PAST MEDICAL HISTORY (PMH)
| # | History | Details |
|---|---|---|
| 1 | S/P ORIF Plating, Left Humerus | 2005 — previous orthopedic surgery, not relevant to current case |
| 2 | Open Appendectomy | 1 week prior — current surgery for acute appendicitis |
Surgical Relevance:
- No prior abdominal surgery besides current appendectomy — this is important because adhesion formation is relevant in any subsequent surgery (e.g., right hemicolectomy if indicated)
- No history of cancer, GI disease, or hereditary syndromes noted
- No known drug allergies documented
SLIDE 5: PERSONAL AND SOCIAL HISTORY / FAMILY HISTORY
Personal and Social History:
| Finding | Clinical Significance | |
|---|---|---|
| Alcohol | Occasional alcoholic beverage drinker | Minimal risk factor; relevant for hepatic metabolism, anesthesia risk |
| Tobacco | Smoker, 1 pack-year | Low cumulative exposure; mild cardiovascular/pulmonary risk |
Family History: Not documented in the case — should be asked about:
- Any family history of Multiple Endocrine Neoplasia type 1 (MEN-1) — associated with pancreatic and other NETs
- History of GI cancers or hereditary cancer syndromes (Lynch, FAP)
- These should be elicited during the follow-up visit as the carcinoid diagnosis is now confirmed
Social Relevance: Young, 25-year-old male — excellent functional baseline; good surgical candidate for any further procedure if indicated
SLIDE 6: PHYSICAL EXAMINATION
Vital Signs:
| Parameter | Value | Interpretation |
|---|---|---|
| BP | 120/80 mmHg | Normal |
| HR | 80 bpm | Normal |
| RR | 20 cpm | Normal |
| Temp | 36.7°C | Afebrile |
| O2 Sat | 98% at room air | Normal |
| Height | 5'6" | — |
| Weight | 50 kg | BMI ~17.7 — mildly underweight |
Physical Exam Findings:
- HEENT: Anicteric sclerae (no jaundice), trachea at midline, no palpable lymphadenopathy
- C/L: Clear breath sounds, equal chest expansion, equal tactile fremitus — no pulmonary compromise
- CV: Adynamic precordium, regular rate and rhythm — notably, no murmur (carcinoid heart disease — tricuspid regurgitation — is absent, appropriate for localized disease)
- Abdomen: (+) Post-op wound at RLQ, well-coaptated, no erythema — healing well, no wound infection signs
- Extremities: Strong peripheral pulses, CRT <2 seconds, Full ROM — no edema, no stigmata of carcinoid syndrome (no flushing, no telangiectasia)
- GUT: (-)KPS — no costovertebral angle tenderness
Overall Impression from PE: Patient appears to be recovering well post-appendectomy with no signs of surgical site infection or systemic disease. No clinical features of carcinoid syndrome (absent because disease is localized — serotonin gets metabolized by the liver before reaching systemic circulation).
SLIDE 7: PRIMARY IMPRESSION / DIAGNOSIS
Pre-histopath Primary Impression:
Acute Appendicitis, NOS — Post-Operative Day 7, Status Post Open Appendectomy
Basis:
- Classical presentation: fever + RLQ pain
- McBurney's point tenderness (presumed at initial admission)
- Leukocytosis (expected at initial admission)
- Confirmed surgically — inflamed appendix with surrounding fat stranding on gross specimen
Post-histopath Primary Impression:
Well-Differentiated Appendiceal Neuroendocrine Tumor (NET G1), Carcinoid, Incidentally Discovered
- Tumor at base of appendix, 1.8–2.8 cm
- Chromogranin A (+), Synaptophysin (+)
- Salt-and-pepper chromatin, nested architecture
SLIDE 8–9: DIFFERENTIAL DIAGNOSIS
The initial presentation of fever + RLQ pain has a broad differential. Here are at least 3:
DDx 1: Acute Appendicitis ✅ (Confirmed initially)
- Clinical features: Fever, anorexia, periumbilical pain migrating to RLQ, rebound tenderness at McBurney's point, Rovsing's sign, psoas sign
- Labs: Leukocytosis with left shift
- Imaging: CT abdomen/pelvis — dilated appendix >6mm, periappendiceal fat stranding, appendicolith
- Most common diagnosis — confirmed in this patient, prompting the open appendectomy
DDx 2: Appendiceal Mucinous Neoplasm (LAMN/HAMN)
- Why consider: RLQ pain, appendiceal mass, bulbar lesion at base
- Difference: Gross appearance is mucin-filled, distended appendix ("mucocele"); microscopy shows mucin-secreting columnar epithelium, NOT neuroendocrine nests
- Danger: Rupture can cause pseudomyxoma peritonei
- Against this case: Histopath showed neuroendocrine cells with chromogranin/synaptophysin positivity, not mucinous cells
DDx 3: Appendiceal Adenocarcinoma
- Why consider: Mass at base of appendix, firm lesion
- Difference: Shows gland-forming structures, mucin production, marked pleomorphism, aggressive invasion
- Against this case: Cells are small and uniform with salt-and-pepper chromatin; IHC shows neuroendocrine markers, not CK20/CDX2-dominant adenocarcinoma profile
DDx 4: Goblet Cell Carcinoid (GCC) / Adenocarcinoid
- Why consider: Hybrid neoplasm, occurs at appendix, can present similarly
- Difference: Shows both glandular (goblet cell) and neuroendocrine differentiation; more aggressive behavior; mixed IHC pattern
- Against this case: Pure neuroendocrine morphology with no mucinous/goblet cell component described; diffuse Chromogranin A and Synaptophysin without CDX2
DDx 5: Mesenteric Lymphadenitis / Crohn's Disease (RLQ mimic)
- Why consider: RLQ pain, fever in young patients
- Difference: No discrete appendiceal mass; ileal wall thickening and skip lesions on imaging/pathology for Crohn's
- Against this case: Appendix was surgically confirmed as the source; no ileitis described
SLIDE 10: INTERPRETATION OF RESULTS
Gross Pathology:
| Finding | Significance |
|---|---|
| Appendix: 90mm long, 7mm diameter | Inflamed — normal diameter is 3–6mm |
| Surrounding fat stranding | Confirms acute periappendiceal inflammation |
| 1.8 cm firm, yellow, bulbar mass at base | Classic gross appearance of carcinoid — firm, yellow-tan, solid |
Microscopic Pathology:
| Finding | Significance |
|---|---|
| 2.8 cm lesion at base, submucosal, nodular | Concerning size — >2 cm = high-risk for metastasis (Schwartz's: 30% metastatic rate at >2 cm) |
| Nested/organoid pattern | Classic architecture of well-differentiated NET |
| Small, uniform cells | Low-grade morphology |
| Round nuclei, central prominent nucleoli | Neuroendocrine cytology |
| Salt-and-pepper chromatin | Pathognomonic for neuroendocrine differentiation |
| Chromogranin A (+) — diffuse | Confirms neuroendocrine secretory granules |
| Synaptophysin (+) — diffuse | Confirms neuroendocrine differentiation (synaptic vesicle marker) |
Histopathology Images from the Case:
Left image (H&E): Shows the classic nested pattern of small uniform cells — "insular" growth pattern typical of midgut-type carcinoid
Right image (IHC — Chromogranin A): Diffuse brown cytoplasmic positivity — confirms neuroendocrine lineage
Classification per WHO 2022 / ENETS:
- NET G1 (if Ki-67 <3%, mitoses <2/10 HPF) — most likely given low-grade morphology
- NET G2 if Ki-67 3–20%
SLIDE 11: FINAL IMPRESSION / DIAGNOSIS
Final Diagnosis:
Appendiceal Well-Differentiated Neuroendocrine Tumor (NET), Grade 1
Incidentally discovered in a background of Acute Appendicitis, Status Post Open Appendectomy
Key diagnostic criteria met:
- ✅ Submucosal, nested/organoid architecture
- ✅ Small, uniform cells with salt-and-pepper chromatin
- ✅ Diffuse Chromogranin A positivity
- ✅ Diffuse Synaptophysin positivity
- ✅ Gross: firm, yellow, bulbar mass at appendix base
- ✅ Size: 2.8 cm (clinically significant — exceeds 2 cm threshold)
Critical Size Implication (per Schwartz's):
- Tumors <1 cm: >95% cure rate with appendectomy alone
- Tumors 1–2 cm: consider clinical factors; may need hemicolectomy
- Tumors >2 cm: appendectomy alone is NOT sufficient — right hemicolectomy is indicated due to ~30% risk of lymph node metastasis
This patient's 2.8 cm tumor → Right Hemicolectomy is indicated
CASE DISCUSSION
SLIDES 12–13: BRIEF ANATOMY AND PHYSIOLOGY
Anatomy of the Appendix
The vermiform appendix is a blind-ended tubular structure arising from the posteromedial wall of the cecum, approximately 2–3 cm below the ileocecal valve. It is a midgut-derived structure.
Key anatomical facts:
| Feature | Detail |
|---|---|
| Length | 2–20 cm, average 9 cm |
| Diameter | 3–8 mm (normal) |
| Position | Variable — retrocecal (most common, 65%), pelvic, subcecal, pre-ileal, post-ileal |
| Blood supply | Appendicular artery (branch of ileocolic artery → from superior mesenteric artery); runs in mesoappendix |
| Venous drainage | Appendicular vein → ileocolic vein → superior mesenteric vein → portal vein |
| Lymphatics | Drain to ileocolic lymph nodes along superior mesenteric artery |
| Innervation | Sympathetic (T10), parasympathetic (vagus nerve) |
Layers of the Appendiceal Wall (inside out):
- Mucosa — columnar epithelium, goblet cells, crypts of Lieberkühn
- Submucosa — rich in lymphoid tissue (250+ lymphoid follicles), site of carcinoid origin
- Muscularis propria — inner circular, outer longitudinal
- Serosa — visceral peritoneum
Neuroendocrine Cells (Enterochromaffin/Kulchitsky Cells):
- Located in the crypts of the mucosa/submucosa
- Part of the diffuse neuroendocrine system (DNES) / APUD system
- Produce serotonin (5-HT), substance P, motilin, and other peptides
- These are the cells of origin of carcinoid tumors
Physiology:
- Appendix has immune function — high density of lymphoid tissue; acts as a "safe house" for gut microbiome
- Neuroendocrine cells regulate gut motility, secretion, and vascular tone via paracrine/endocrine signaling
- Serotonin produced by enterochromaffin cells → vasoactive; in excess (metastatic NET) causes carcinoid syndrome
SLIDES 14–15: DEFINITION, PATHOPHYSIOLOGY, ETIOLOGY & RISK FACTORS
Definition
A Neuroendocrine Tumor (NET), previously called "carcinoid tumor," is a neoplasm arising from the enterochromaffin (Kulchitsky) cells of the neuroendocrine system. In the appendix, these are the most common primary tumor (accounts for 50–77% of appendiceal tumors).
Per WHO 2022 classification:
- NET G1: Ki-67 <3%, mitoses <2/10 HPF
- NET G2: Ki-67 3–20%, mitoses 2–20/10 HPF
- NET G3: Ki-67 >20% (well-differentiated but high proliferation)
- NEC (Neuroendocrine Carcinoma): High grade, poorly differentiated
Pathophysiology
Step 1 — Origin:
Kulchitsky/enterochromaffin cells in appendiceal crypts undergo neoplastic transformation → form clusters → expand into submucosa
Step 2 — Growth Pattern:
- Slow-growing (doubling time: months to years)
- Organoid/insular architecture — nests surrounded by fibrovascular stroma
- Invades submucosa → muscularis propria → mesoappendix → regional nodes
Step 3 — Secretory Function:
- Produce serotonin (5-HT), substance P, histamine, bradykinin
- In localized disease: metabolized by liver → no systemic syndrome
- In metastatic disease (especially liver mets): serotonin bypasses hepatic metabolism → Carcinoid Syndrome:
- Episodic flushing
- Secretory diarrhea
- Bronchospasm
- Right-sided cardiac valvular disease (carcinoid heart disease)
Step 4 — Malignant Potential by Size (Schwartz's):
| Tumor Size | Metastasis Rate |
|---|---|
| <1 cm | <2% |
| 1–2 cm | ~10% |
| >2 cm | ~30% |
Etiology
- Sporadic — majority of cases; no identified genetic cause
- MEN-1 (Multiple Endocrine Neoplasia Type 1) — rare association
- NF-1 (Neurofibromatosis Type 1)
- No direct causation from alcohol or tobacco
Risk Factors
| Factor | Detail |
|---|---|
| Age | Peak: 40s–50s (but can occur at any age, including 25 as in this case) |
| Sex | Slight female predominance for appendiceal carcinoid |
| Race | Higher incidence in Black Americans |
| MEN-1 | Germline MEN1 mutation — associated with multiple NETs |
| Prior appendicitis | May theoretically promote microenvironmental changes |
| Chronic atrophic gastritis | Risk factor for gastric NETs specifically |
SLIDE 16: DIAGNOSTICS (IDEAL LABORATORY AND IMAGING STUDIES)
Laboratory Studies
| Test | Rationale |
|---|---|
| CBC with differential | Leukocytosis in acute appendicitis; baseline pre-operative |
| Serum Chromogranin A (CgA) | Primary biomarker for NETs; elevated in >80% of NETs; correlates with tumor burden |
| 24-hour urinary 5-HIAA (5-hydroxyindoleacetic acid) | Metabolite of serotonin; elevated in functional/metastatic carcinoid; sensitivity ~70% |
| Serum serotonin | Direct measure; useful if 5-HIAA unavailable |
| Serum pancreastatin | More specific NET marker, less affected by diet than CgA |
| LFTs, AFP | Evaluate for liver metastases |
| BMP/CMP | Metabolic baseline |
| Coagulation studies | Pre-operative if hemicolectomy planned |
Imaging Studies
| Modality | Use |
|---|---|
| CT Abdomen/Pelvis with contrast (3-phase) | Evaluate for mesenteric/lymph node involvement, liver mets; NET mets are hypervascular — best seen on arterial phase |
| MRI Abdomen | Superior to CT for detecting small liver metastases; no radiation |
| Ga-68 DOTATATE PET/CT (Somatostatin Receptor PET) | Gold standard functional imaging; detects somatostatin receptor-positive NETs; superior to OctreoScan |
| Octreotide Scan (In-111 OctreoScan) | Older alternative to Ga-68 DOTATATE; detects SSTR2-positive tumors; identifies distant mets |
| Echocardiography | If elevated 5-HIAA: screen for carcinoid heart disease (tricuspid regurgitation, pulmonary stenosis) |
| Endoscopy (colonoscopy) | Evaluate cecum and appendiceal orifice; assess base margins |
SLIDES 17–23: MANAGEMENT
Pre-operative Management (for the upcoming Right Hemicolectomy)
Indication: Tumor size 2.8 cm — exceeds the >2 cm threshold per Schwartz's Principles of Surgery → Right Hemicolectomy is the standard of care
Pre-op workup:
- Complete staging: CT abdomen/pelvis + chest (3-phase); Ga-68 DOTATATE PET/CT
- Biomarkers: Serum CgA, 24-hr urine 5-HIAA → establish baseline
- Echocardiography: Rule out carcinoid heart disease before surgery
- Optimization: Correct anemia/malnutrition — this patient is mildly underweight (50 kg, 5'6"), consider nutritional support
- Bowel preparation: Mechanical bowel prep + oral antibiotics (per institutional protocol) — essential before hemicolectomy
- DVT prophylaxis: LMWH + TED stockings initiated pre-operatively
- Informed consent: Discuss right hemicolectomy, anastomosis, risks, ostomy possibility
- Anesthesia clearance: Standard pre-anesthetic evaluation; note prior ORIF surgery (musculoskeletal history)
Note on Octreotide: Pre-operative octreotide infusion is indicated if the patient has carcinoid syndrome (flushing, diarrhea) to prevent carcinoid crisis during anesthesia/surgery. In this patient (no syndrome, localized disease), it may not be mandatory but should be available intraoperatively.
Neoadjuvant Treatment
Not applicable in standard localized appendiceal NET G1. These tumors are resection-first — there is no role for neoadjuvant chemotherapy or radiation in well-differentiated, localized appendiceal NETs. Neoadjuvant approaches are reserved for unresectable or borderline-resectable high-grade NECs.
Surgical Treatment: Right Hemicolectomy
Indication in this case: Appendiceal NET ≥2 cm with potential mesoappendiceal invasion
Goal: Achieve R0 resection with adequate lymph node sampling (minimum 12 nodes)
Procedure Description:
Step 1 — Positioning and Access:
- Patient supine, general endotracheal anesthesia
- Open (midline laparotomy) or laparoscopic approach (preferred if expertise available)
- Explore peritoneal cavity — assess for liver metastases, peritoneal implants, lymphadenopathy
Step 2 — Mobilization of the Right Colon:
- Incise the lateral peritoneal attachments (white line of Toldt) from terminal ileum to hepatic flexure
- Medial-to-lateral dissection preferred laparoscopically
- Dissect in the avascular retroperitoneal plane (anterior to Gerota's fascia)
- Protect ureter, gonadal vessels, duodenum
Step 3 — Vascular Ligation (D3 Lymphadenectomy):
- Ligate the ileocolic artery and vein at their origins from the superior mesenteric vessels → ensures oncologic nodal clearance
- Divide right colic artery if present
- Right branch of middle colic artery may be divided depending on hepatic flexure involvement
Step 4 — Bowel Division:
- Divide terminal ileum ~10–15 cm proximal to ileocecal valve using linear cutting stapler
- Divide transverse colon at the mid-transverse level
- Remove specimen including: terminal ileum, cecum, ascending colon, hepatic flexure, mesentery with lymph nodes
Step 5 — Anastomosis:
- Ileocolic anastomosis (side-to-side or end-to-end):
- Stapled (preferred) or hand-sewn
- Tension-free, adequate blood supply confirmed
- Side-to-side functional end-to-end anastomosis is most common
Step 6 — Closure:
- Inspect anastomosis and hemostasis
- Close mesenteric defect to prevent internal herniation
- Layer-by-layer fascial closure; skin closure
Post-operative Complications and Management
| Complication | Incidence | Management |
|---|---|---|
| Anastomotic leak | 1–5% | NPO, IV antibiotics, CT-guided drainage vs. re-exploration |
| Surgical site infection (SSI) | 5–15% | Wound opening, antibiotics, wound care |
| Ileus | Common (3–5 days) | NPO/clear liquids, ambulation, chewing gum (enhanced recovery) |
| Intra-abdominal abscess | 2–5% | CT-guided drainage, antibiotics |
| Bleeding | <2% | Transfusion, re-exploration if hemodynamically unstable |
| DVT/PE | 1–3% | LMWH prophylaxis continued; therapeutic anticoagulation if confirmed |
| Urinary retention | Common | Foley catheter, alpha-blockers |
| Carcinoid crisis | Rare intraoperatively | IV octreotide bolus (300–500 mcg) + infusion |
Enhanced Recovery After Surgery (ERAS) Protocol:
- Early oral intake (clear liquids POD0–1)
- Early mobilization
- Multimodal pain management (minimize opioids)
- Remove urinary catheter POD1–2
- Target discharge: POD 3–5
Adjuvant Therapy and Surveillance
Adjuvant Chemotherapy / Radiation:
- Not indicated for completely resected (R0) NET G1/G2
- Reserved for: incomplete resection (R1/R2), high-grade NEC, or metastatic disease
Somatostatin Analogs (SSA) — Octreotide LAR / Lanreotide:
- Indication in resected disease: If evidence of residual disease, high Ki-67, or metastatic component
- Antiproliferative effect: PROMID trial (octreotide LAR) and CLARINET trial (lanreotide) showed significant improvement in progression-free survival in metastatic midgut NETs
- Dose: Octreotide LAR 20–30 mg IM every 4 weeks; Lanreotide 120 mg deep SC every 4 weeks
PRRT (Peptide Receptor Radionuclide Therapy — Lu-177 DOTATATE):
- Indicated for metastatic, somatostatin receptor-positive NETs
- NETTER-1 trial: significant PFS benefit vs. high-dose octreotide in midgut NET
- Not indicated for this patient if R0 resection achieved
Surveillance Protocol (post-curative resection of appendiceal NET >2 cm):
| Timepoint | Action |
|---|---|
| Every 3–6 months × 3 years | Serum CgA, 24-hr urine 5-HIAA |
| 6 months post-op | CT abdomen/pelvis (3-phase) |
| Annually × 5 years | CT abdomen/pelvis |
| Annually | Clinical exam, biomarkers |
| If symptoms arise (flushing, diarrhea) | Echocardiography, Ga-68 DOTATATE PET/CT |
| After 5 years (if disease-free) | Reduce surveillance frequency |
SLIDES 24–25: CASE RESOLUTION
Complete Management Plan for J.C.
Current status: POD 7 post Open Appendectomy, wound well-healing, asymptomatic
STEP 1 — IMMEDIATE (This follow-up visit):
- Review histopath: 2.8 cm appendiceal NET, Chromogranin A (+), Synaptophysin (+)
- Counsel patient on diagnosis: incidental carcinoid, implications of size >2 cm
- Recommend completion Right Hemicolectomy — explain rationale (lymph node risk ~30% at this size)
- Wound care instructions — suture removal at 10–14 days
STEP 2 — STAGING WORKUP (Next 1–2 weeks):
- CT abdomen/pelvis/chest with triple phase contrast — assess lymph nodes, liver, peritoneum, lung
- Serum Chromogranin A (baseline)
- 24-hour urine 5-HIAA (baseline functional marker)
- Ga-68 DOTATATE PET/CT — somatostatin receptor imaging for staging
- Echocardiography — screen for carcinoid heart disease
- Oncology referral — multidisciplinary tumor board discussion
STEP 3 — SURGERY (Once staging complete, ~2–4 weeks post-appendectomy, once patient fully recovered):
- Right Hemicolectomy (open or laparoscopic)
- Adequate lymphadenectomy (≥12 nodes)
- Intraoperative octreotide available
- ERAS protocol
STEP 4 — POST-OP MANAGEMENT:
- ERAS protocol: early ambulation, multimodal analgesia, early feeding
- DVT prophylaxis
- Target discharge POD 3–5
- Wound and drain management
STEP 5 — PATHOLOGY OF HEMICOLECTOMY SPECIMEN:
- Assess: lymph node involvement (number positive/total), resection margins (R0 vs R1), vascular/perineural invasion, Ki-67 index
- Final staging (TNM per AJCC/ENETS):
- T3 (>2 cm or mesoappendix invasion) N0/N1 M0
STEP 6 — ADJUVANT THERAPY:
- If R0, N0: Surveillance only — no adjuvant chemotherapy
- If N1 (nodal mets) or R1: Somatostatin analog (Octreotide LAR or Lanreotide)
- If distant mets discovered: multidisciplinary management — SSA, PRRT (Lu-177 DOTATATE), cytoreductive surgery
STEP 7 — LONG-TERM SURVEILLANCE:
- Serum CgA + 24-hr urine 5-HIAA every 3–6 months × 3 years, then annually
- CT abdomen/pelvis every 6–12 months × 5 years
- Annual clinical review for carcinoid syndrome symptoms (flushing, diarrhea, wheezing)
- Echocardiography if symptoms or rising 5-HIAA
PROGNOSIS:
| Scenario | 5-Year Survival |
|---|---|
| Localized, R0 resection (<2 cm) | >95% |
| Localized, R0 resection (this patient, 2.8 cm with hemicolectomy) | ~85–90% |
| Regional nodal disease | ~65–70% |
| Distant metastases | ~35–50% |
Summary Table
| Aspect | Finding / Decision |
|---|---|
| Patient | 25M, post-appendectomy |
| Histopath | Well-differentiated NET G1, 2.8 cm base of appendix |
| IHC | Chromogranin A (+), Synaptophysin (+) |
| Critical finding | Size >2 cm → lymph node risk ~30% |
| Next surgery | Right Hemicolectomy |
| Staging | CT 3-phase + Ga-68 DOTATATE PET/CT |
| Biomarkers | CgA + 24-hr urine 5-HIAA |
| Adjuvant (if R0 N0) | Surveillance only |
| Adjuvant (if N1/R1) | Octreotide LAR or Lanreotide |
| Surveillance | q3–6 months × 3yr, then annually |
Reference: Schwartz's Principles of Surgery, 11th Edition — Chapter on Small Intestine and Appendix; ENETS Consensus Guidelines 2023; NANETS Guidelines; WHO Classification of Tumors 2022 (Digestive System)
This is a shared conversation. Sign in to Orris to start your own chat.